AIMS develops new drug for leukaemia

Published: 16th October 2012 09:06 AM  |   Last Updated: 16th October 2012 09:06 AM   |  A+A-

The Amrita Centre for Nanosciences and Molecular Medicine under the Amrita Institute of Medical Sciences and Research Centre(AIMS) has announced that they have developed a new drug for leukaemia patients.

The Centre has developed a nanomedicine which has shown significant ability to kill the cancer cells that are drug resistant, said a statement issued by the Amrita Centre for Nanosciences and Molecular Medicine. In certain cases the patients suffering from Chronic Myeloid Leukemia (CML) have little chances of survival due to resistance to the drug Imatinib. Drug resistance arises due to certain point mutations in the leukaemia cells.

The new medicine has been developed considering these factors over a period of three years and has shown success in in-vitro studies.

The Centre is now conducting animal trials as part of the pre-clinical studies. If the pre-clinical trials are successful, the new nanomedicine may be submitted for clinical trial approval to the Union Government of India, the statement said.

The senior scientists involved in the research were Dr Manzoor Koyakutty, professor, and Dr Shantikumar Nair, Centre Director and Dean of Research. Clinicians from the hospital - Dr Pavithran, Dr Neeraj and Dr Prabhu - along with a student Archana Ratnakumari were involved in the project.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp